Company / Operating Cash Flow per Share
Rapport Therapeutics, Inc. Operating Cash Flow per Share History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.13
FY2024
5-year range
-$18.05 / -$3.13
FY2023-FY2024
Trend
+82.7%
vs FY2023
Sector context
#171 of 212
Health Care
What the data says
Rapport Therapeutics, Inc.'s operating cash flow per share of $-3.13 is lower than 81% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
-3.13 in FY2024.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 212This company -$3.13 Sector average -$14.72
▼
+78.8% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 82.7% year-over-year.
- Ranks #171 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.13 | +82.7% |
| FY2023 | -$18.05 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026